Publications
- The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms2022 | First Faculty of Medicine
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study2021 | First Faculty of Medicine
- Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors2020 | First Faculty of Medicine
- Neuroendocrine tumors in cases2018 | First Faculty of Medicine
- Everolimus in therapy of lung and gastrointestinal neuroendocrine tumors - comments on Radiant-42017 | First Faculty of Medicine
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study2016 | First Faculty of Medicine
- ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas2016 | First Faculty of Medicine
- The ENETS Consensus Quidelines 2016 - somatostatin analogues in the treatment of neuroendocrine tumors2016 | First Faculty of Medicine
- OLE study - Open Label Extension study phase Clarinet with lanreotide Autogel 120 mg in metastatic enteropancreatic neuroendocrine tumors2016 | First Faculty of Medicine
- Neuroendocrine tumors in 20162016 | First Faculty of Medicine
Loading network view...
